In angioplasty procedures, a balloon is fed through a catheter and used to prop open an artery that has become narrowed or blocked. In cases where stenting is appropriate, a stent mounted on a balloon is inserted and inflation of the balloon expands the stent against the blocked artery wall to hold the vessel open. The balloon is then deflated and the catheter is withdrawn. Stent treatment of arteries holds them open and improves blood flow to the heart. In cases where post-dilatation is needed, a high-pressure balloon is inflated inside a stent to help better place the stent against the vessel wall.
Intact Vascular, Inc., a private medical device company committed to developing solutions for minimally invasive peripheral vascular procedures, today announced it received U.S. Food and Drug Administration approval for the Tack Endovascular System, a purpose-built dissection repair device implanted post-angioplasty in patients with peripheral arterial disease.
Nearly 3 million Americans are living with atrial fibrillation (AFib), which is described as quivering or irregular heartbeat (arrhythmia).
The "First international consensus on the diagnosis and management of fibromuscular dysplasia" (FMD) has been published online first today in Vascular Medicine and the Journal of Hypertension.
Patients who arrive at the hospital with heart-attack-like symptoms have had little recourse for their chest pain if scans came back clear, with no signs of blocked coronary arteries. Some of these cases are caused by a little-known phenomenon called coronary slow flow.
Every year millions of people undergo medical tests and procedures, such as coronary angiography, which use intravascular contrast dyes.
Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced that data from its Tack Optimized Balloon Angioplasty II pivotal clinical trial will be presented at the 15th Annual VIVA Conference in Las Vegas, NV on November 5-8.
Cook Medical announced that a new 5 mm diameter version of Zilver® PTX® was approved by the FDA. It is the first 5 mm drug-eluting stent in the U.S. with lengths available up to 140 mm that is indicated to treat vessels as small as 4mm in diameter.
In the current issue of Cardiovascular Innovations and Applications (Volume3, Number 2, 2018, pp. 203-214(12); DOI: https://doi.org/10.15212/CVIA.2017.0046 Ahmad A. Mahmoud, Ahmed N. Mahmoud, Akram Y. Elgendy and R. David Anderson from the Division of Cardiovascular Medicine, Department of Medicine, University of Florida, Gainesville, FL, USA consider the current status of coronary atherectomy.
Cristina Sabliov, LSU Biological and Agricultural Engineering professor, and Tammy Dugas, professor in the LSU School of Veterinary Medicine's Department of Comparative Biomedical Sciences, have joined forces to fight peripheral artery disease, or PAD, an ailment affecting 8 million Americans.
A removable balloon is as good as a permanent stent implant for opening small blocked arteries, according to late breaking results from the BASKET-SMALL 2 trial presented in a Hot Line Session today at ESC Congress 2018 and simultaneously published in The Lancet.
Treatments that restore blood flow to the lower limbs of people with a serious circulation condition may be cheaper and associated with longer survival, than amputation according to new research in Journal of the American Heart Association, the Open Access Journal of the American Heart Association/American Stroke Association.
Today, the U.S. Food and Drug Administration permitted marketing of two catheter-based devices designed to create a connection to veins and arteries in patients with chronic kidney disease who need hemodialysis.
The newer high-sensitivity troponin test discovers smaller amounts of heart-specific proteins, troponins, than the older troponin test and thus identifies more myocardial infarction patients than before.
Using genetic testing to inform which blood thinner to use following a procedure to open narrowed blood vessels resulted in significantly fewer complications among patients, according to new research in Circulation: Genomic and Precision Medicine, an American Heart Association journal.
The combined rate of death from any cause, heart attack or stroke within 18 months was not significantly different in patients with acute coronary syndrome who were randomly assigned to receive dual antiplatelet therapy for either six months or at least 12 months after receiving a drug-eluting stent.
Cleveland Clinic researchers found that implementing a four-step protocol for the most severe type of heart attack not only improved outcomes and reduced mortality in both men and women, but eliminated or reduced the gender disparities in care and outcomes typically seen in this type of event.
Simply changing cardiac referral processes to opt-out rather than opt-in significantly increased referral rates, according to a study presented at the American College of Cardiology's NCDR Annual Conference in Orlando.
Cardiologists at the Catharina hospital in Eindhoven have succeeded in the localized cooling of the heart during a heart attack, a world first. By cooling part of the heart prior to and following angioplasty, the cardiologists believe that the damage from a heart attack can be limited.
PLAQUETEC LTD today announced the publication of the first peer‐reviewed article demonstrating the feasibility and potential of the PlaqueTec Liquid Biopsy System™ to detect biomarkers for coronary artery disease (CAD).
A new long-term look at heart attack care and spending in America since the turn of the century shows more survival, more spending, and more variation between hospitals on both scores.